Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
20 valent pneumococcal polysaccharide conjugate vaccine (Minhai Biological) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
20 valent pneumococcal polysaccharide conjugate vaccine (Minhai Biological): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers.
8 min read
Anti-MUC1 CAR T cell(Guangzhou Anjie Biomedical Technology Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Anti-MUC1 CAR T cell(Guangzhou Anjie Biomedical Technology Co., Ltd.): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical.
8 min read
LPM6690176 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
LPM6690176: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
KUS-121 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
KUS-121: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LN003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
LN003: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ABO-1108 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ABO-1108: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
KSP-0243 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
KSP-0243: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ECC-0509 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ECC-0509: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SHR-3821 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
SHR-3821: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Recombinant anti-TNFα monoclonal antibody(Livzon Pharmaceutical Group, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
Recombinant anti-TNFα monoclonal antibody(Livzon Pharmaceutical Group, Inc.): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review.
8 min read
ZPL-5212372 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
ZPL-5212372: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RGT-274-CR Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
4 August 2026
RGT-274-CR: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.